Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Lowered to $600.00 at BMO Capital Markets

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) had its price target decreased by BMO Capital Markets from $800.00 to $600.00 in a research note issued on Monday,Benzinga reports. The brokerage currently has an "outperform" rating on the biopharmaceutical company's stock. BMO Capital Markets' price target would suggest a potential upside of 22.99% from the company's current price.

REGN has been the subject of several other reports. TD Cowen reduced their target price on Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a "buy" rating for the company in a research note on Tuesday, February 4th. UBS Group reduced their target price on Regeneron Pharmaceuticals from $768.00 to $633.00 and set a "neutral" rating for the company in a research note on Wednesday, April 30th. The Goldman Sachs Group reduced their target price on Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating for the company in a research note on Wednesday, April 30th. JPMorgan Chase & Co. reduced their target price on Regeneron Pharmaceuticals from $1,100.00 to $1,000.00 and set an "overweight" rating for the company in a research note on Monday, March 31st. Finally, Cantor Fitzgerald initiated coverage on Regeneron Pharmaceuticals in a research note on Tuesday, April 22nd. They set an "overweight" rating and a $695.00 target price for the company. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have issued a buy rating and three have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $847.40.

Regeneron Pharmaceuticals Stock Performance

Regeneron Pharmaceuticals stock traded down $2.95 during mid-day trading on Monday, hitting $487.86. The company had a trading volume of 2,139,444 shares, compared to its average volume of 844,356. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals has a 12-month low of $481.58 and a 12-month high of $1,211.20. The company's fifty day moving average is $581.26 and its 200-day moving average is $663.80. The company has a market capitalization of $52.67 billion, a price-to-earnings ratio of 12.74, a P/E/G ratio of 2.34 and a beta of 0.43.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing the consensus estimate of $8.83 by ($0.61). Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The company had revenue of $3.03 billion during the quarter, compared to analysts' expectations of $3.40 billion. During the same quarter in the prior year, the company posted $9.55 EPS. The company's revenue for the quarter was down 3.7% on a year-over-year basis. Equities research analysts predict that Regeneron Pharmaceuticals will post 35.92 EPS for the current year.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

A number of hedge funds have recently modified their holdings of REGN. Capital International Investors grew its holdings in shares of Regeneron Pharmaceuticals by 41.6% during the 4th quarter. Capital International Investors now owns 4,736,929 shares of the biopharmaceutical company's stock worth $3,373,859,000 after purchasing an additional 1,390,534 shares during the period. Norges Bank purchased a new position in Regeneron Pharmaceuticals during the 4th quarter valued at about $802,036,000. GAMMA Investing LLC boosted its holdings in Regeneron Pharmaceuticals by 89,825.0% during the 1st quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company's stock valued at $517,291,000 after acquiring an additional 814,713 shares during the period. Price T Rowe Associates Inc. MD boosted its holdings in Regeneron Pharmaceuticals by 63.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,085,447 shares of the biopharmaceutical company's stock valued at $1,485,527,000 after acquiring an additional 810,144 shares during the period. Finally, Nuveen LLC purchased a new position in Regeneron Pharmaceuticals during the 1st quarter valued at about $343,764,000. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.